During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|March 30, 2018
Relapsed Follicular Lymphoma
Relapsed Follicular Lymphoma
Advertisement
October 2014
- A 72-year-old man presents to his physician complaining of fatigue lasting several months, recent weight loss of 15 lbs. and a mass on his right side of neck
- PMH: GI reflux controlled on PPI, obstructive sleep apnea
- PE: Right supraclavicular lymph node (7 cm.), spleen palpable 5 cm. below the costal margin
- Performance status, 1
- Laboratory findings:
- Hb, 9.9 g/dL ,
- Leukocytes, 3.21 X 109/L
- Platelets, 110 X 109/L
- AST, 162 U/L; ALT 201 U/L
- LDH, 302 U/L
- Excisional biopsy of the right supraclavicular node:
- IHC staining, CD10+, Bcl2+, CD5-
- Follicular lymphoma, grade 2
- Bone marrow; paratrabecullar infiltration by small cleaved lymphocytes
- PET-CT showed enlargement of right supraclavicular lymph node (3 X 7 cm) and 3 mediastinal lymph nodes (3.2 cm, 3.5 cm, 4.4 cm); diffusely enlarged nodes in the retroperitoneal, mesentery, and inguinal regions: SUVmax, 9
- FLIPI, 5 points, high risk
- The patient was treated by the local oncologist with R-CHOP (6 cycles)
- Post-treatment he achieved a partial metabolic response
- He was continued on rituximab maintenance therapy and his disease remained stable
July 2016
- 23 months later, the patient complained of his symptoms returning
- PET revealed enlargement of the affected mediastinal nodes
- SUVmax of all nodes was 12
- Repeat CT revealed progression of disease
- The patient was started on bendamustine + rituximab (6 cycles) and achieved a partial response after completing induction therapy
January 2018
- Sixteen months later, the patient reports feeling tired but could resume most normal activities (ECOG 1)
- PET with diagnostic CT showed diffuse18F-FDG uptake in multiple lymph nodes and spleen; the largest involved nodes are the right supraclavicular (6.2 cm), left mesenteric (4.8 cm), and splenic hilar (2.7 cm) nodes
- Repeat biopsy showed grade 2 follicular lymphoma
- The patient was started on copanlisib
- After three months, he developed a partial response with>50% reduction in lymphadenopathy in all involved nodes
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5